secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001104659-26-031795
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance reports Q4/FY2025 financials; restructuring after Phase 3 failure; strategic review ongoing
--------------------------------------------------------------------------------

- Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.
- TRELEGY net sales $3.9B (+12% YoY) triggered $50M milestone; confident in $100M 2026 milestone.
- Restructuring after failed Phase 3 CYPRESS study; expects $60-70M annualized cash savings starting Q3 2026.
- Cash ~$400M at end Q1 2026; no debt.
- Strategic Review Committee accelerating evaluation of alternatives including potential sale of company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926031795/0001104659-26-031795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926031795/tm269321d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-031795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer